The IN-ARMOR project successfully held its 11th Management Board Meeting on 19 December 2025. The meeting brought together consortium partners to review technical and managerial progress, with a focus on advancing the project’s ISI-based antimicrobial peptide drug candidates. These innovative therapies harness innate immunity to fight pathogens, helping reduce reliance on conventional antibiotics.

Work package leaders shared key achievements, discussed upcoming milestones, and aligned on strategic next steps to maximise impact across research, exploitation, and communication activities. The discussions also reinforced the project’s contribution to the long-term fight against antimicrobial resistance (AMR).

The consortium thanks all partners for their continued collaboration and commitment as IN-ARMOR advances its journey from science to market, delivering innovative solutions to one of today’s most pressing health challenges.